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VaccineLumpy skin disease is of signiﬁcant economic impact for the cattle industry in Africa. The disease is cur-
rently spreading aggressively in the Near East, posing a threat of incursion to Europe and Asia. Due to
cross-protection within the Capripoxvirus genus, sheep pox virus (SPPV) vaccines have been widely used
for cattle against lumpy skin disease virus (LSDV). In the Middle East and the Horn of Africa these vac-
cines have been associated with incomplete protection and adverse reactions in cattle post-vaccination.
The present study conﬁrms that the real identity of the commonly used Kenyan sheep and goat pox vac-
cine virus (KSGP) O-240 is not SPPV but is actually LSDV. The low level attenuation of this virus is likely to
be not sufﬁcient for safe use in cattle, causing clinical disease in vaccinated animals. In addition, Isiolo
and Kedong goat pox strains, capable of infecting sheep, goats and cattle are identiﬁed for potential
use as broad-spectrum vaccine candidates against all capripox diseases.
Crown Copyright  2014 Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction disease is detected at a very early stage and control measures areLumpy skin disease virus (LSDV), sheep pox virus (SPPV) and
goat pox virus (GTPV) comprise the Capripoxvirus genus within
the Poxviridae family (Buller et al., 2005). Sheep pox (SPP) and goat
pox (GTP) are endemic in northern and central Africa and in large
parts of Asia. Lumpy skin disease (LSD) occurs across Africa and has
recently been aggressively spreading in the Middle East, despite
excessive vaccination campaigns carried out in the region. The lat-
est outbreaks of LSD were reported to the World Organization for
Animal Health (OIE) Wahid database from Turkey and Iraq, raising
concerns that the disease will continue to spread to Europe and
Asia. All cattle breeds, ages and sexes are affected, although the
disease is more severe in young animals and cows in the peak of
lactation (Weiss, 1968), causing severe production losses through-
out the cattle industry.
It is widely agreed that vaccination is the only effective way to
control the spread of LSDV in endemic countries. In previously dis-
ease-free countries, slaughter of infected and in-contact animals
and movement restrictions have been effective, as long as theimplemented without delay. However, if the disease has acciden-
tally gone unnoticed, allowing time for vectors to become infected,
it is difﬁcult if not impossible, to eradicate the disease without vac-
cination. In resource-limited countries, slaughter of infected and
in-contact animals is seen as a waste of a valuable source of food
and is not usually feasible. In addition, in affected regions, it is
often impossible to effectively implement movement restrictions
for small and large ruminants (Kitching, 1986). Cross-immunity
is known to occur between the members of the genus Capripoxvirus
(Kitching, 1983). Because SPP and GTP do not occur in southern
Africa, only attenuated LSDV vaccines are used against LSDV in
the region. Whereas, in central and northern Africa and in the Mid-
dle East, where the distribution of SPP, GTP and LSD overlap, atten-
uated SPPV vaccines, such as KSGP O-240, Yugoslavian RM65 and
Romanian SPPV strains, have been used against LSDV (Brenner
et al., 2009; Davies, 1991; Kitching, 1986; Somasundaram, 2011).
Because the strain KSGP O-240 infected sheep and goats, caus-
ing only mild clinical disease, it was long considered as an ideal
vaccine candidate against both SPP and GTP. In addition, it was sur-
prisingly easily attenuated, after only 6 passages on cell cultures
(Kitching et al., 1987). Incomplete protection against LSD has been
reported in cattle vaccinated with all SPP vaccines (Ali et al., 1990;
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Somasundaram, 2011). On the other hand, the KSGP O-180 strain,
collected from sheep during the same epizootics but at different
time points than the KSGP O-240 strain (Davies, 1976; Davies
and Otema, 1978), was successfully used in Kenya as a vaccine
against SPPV, GTPV and LSDV without adverse reactions. The dif-
ference was that KSGP O-180 isolate had been attenuated by pas-
saging the virus 18 times on bovine fetal muscle cells. The
efﬁcacy of the vaccine for sheep, goats and cattle was demon-
strated by a challenge experiment and in the ﬁeld (Davies and
Mbugwa, 1985).
Lumpy skin disease was reported in Kenya for the ﬁrst time in
1957 (MacOwan, 1959). The disease was introduced to a mixed
cattle and sheep farm near Nakuru by indigenous sheep infected
with SPPV originating from the nearby Baringo district of Kenya.
Sheep and Ayrshire calves were penned together at night. Soon
after arrival, the lambs started to show clinical signs of SPP fol-
lowed by a similar condition in the calves (Burdin and Prydie,
1959). During the same time period, SPPV was isolated from SPP
samples from the Isiolo district and the Kedong Valley (Capstick,
1959). The Isiolo strain is known to experimentally infect cattle
(Capstick, 1959) and the Kedong strain has been used as a vaccine
for cattle against LSDV in Kenya (Coakley and Capstick, 1961).
In general, capripoxviruses (CaPV) are considered to be very
host-speciﬁc (Babiuk et al., 2009). In addition to the isolate KSGP
O-240, only a few other SPPV and GTPV strains have been known
to affect both sheep and goats (Asagba and Nawathe, 1980; Yan
et al., 2012). However, no reports exist on CaPV infecting all three
species: sheep, goats and cattle. The major difference between the
African and the Middle Eastern and Indian SPP and GTP strains
seems to be the wider host range of the African isolates (Davies,
1976). The Kenya sheep-1 (KS-1) strain is derived from the atten-
uated KSGP O-240 vaccine strain (Chand et al., 1994; Gershon
and Black, 1989). Recent molecular studies have reported a close
relationship between the KS-1 and LSDV, suggesting that KS-1 is
actually LSDV (Tulman et al., 2002). Later this ﬁnding was con-
ﬁrmed by sequencing the host-speciﬁc G-protein-coupled chemo-
kine receptor (GPCR), or RNA polymerase (RPO30) genes, which
revealed the phylogenetic grouping of CaPVs (Lamien et al.,
2011a,b; Le Goff et al., 2005, 2009). Members of the Capripox genus
cannot be distinguished using serological methods (Kitching,
2003). A recently published real-time PCR assay provides a simple
tool for differentiation of CaPV strains (Lamien et al., 2011b). Here
we report the molecular characterization of the virulent Kenyan
KSGP O-240 ﬁeld strain, Isiolo and Kedong SPP isolates and the
attenuated KS-1 and KSGP O-240 vaccine strains held in The Pir-
bright Institute reference virus collection. Selected commercially
available SPPV vaccines against LSDV, used for cattle in the Middle
East and northern and central Africa, were also analyzed.2. Materials and methods
2.1. Virus isolates and vaccines
Virulent KSGP O-240 ﬁeld strain of 3rd passage (p), Isiolo SPPV
(9th p) and Kedong SPPV (2nd p) and the following attenuated vac-
cine viruses: KS-1 isolate, Kenyavac (KSGP O-240) and Jovivac
(RM65) vaccines by Jordan Bio-Industries Centre (JOVAC); and
Sheep Pox Vaccine (Romanian SPPV) by Saudi Arabian Veterinary
Vaccine Institute (SAVVI), were included in this study (Table 1).2.2. General capripoxvirus real-time PCR
DNA was extracted from virus suspensions using DNeasy Blood
& Tissue Kit (Qiagen, UK) following themanufacturer’s instructions.The presence of viral DNA in the samples was quantiﬁed using a
previously described general CaPV real-time PCR. Primers and a
probe were used in combination with a QuantiFast Probe PCR Kit
(Qiagen, Crawley, UK) in a Mx3005p Multiplex Quantitative PCR
System (Strategene, Netherlands) (Bowden et al., 2008; Stubbs
et al., 2012).2.3. Species-speciﬁc real-time PCR
In order to identify which of the three CaPV strains were pres-
ent in each sample, a species-speciﬁc real-time PCR method was
used (Lamien et al., 2011b). The PCR assay detects differences in
the melting point temperatures for SPPV, GTPV and LSDV, obtained
after ﬂuorescence melting curve analysis. It targets a 200 bp region
within the GPCR gene. Samples were run on the Mx3005p Multi-
plex Quantitative PCR System (Strategene, Netherlands) and melt-
ing curves were analyzed to determine the CaPV strain.
Mongolian GTPV (2008) was used as a positive control for GTPV,
Mongolian SPPV (2007) for SPPV and South African LSDV Neethling
strain for LSDV (Kitching et al., 1989). RNase free water was used as
a negative control in all PCR runs.2.4. Sequencing
Full length GPCR and RPO30 genes were generated by ampliﬁ-
cation of overlapping fragments using primers pairs described by
Gelaye et al. (submitted in 2014). In each reaction, 4 ll of the viral
DNA was mixed with 12.5 ll KOD Hot Start Master Mix (Merck,
Germany) and 1 ll (10 lM) of each forward and reverse primer
in total volume of 25 ll. The DNA was initially denaturated at
95 C for 2 min and ampliﬁcation was carried out in 35 cycles of
95 C for 20 s, 65 C for 10 s, 70 C for 20 s. The ampliﬁcation prod-
ucts were visualized and assessed for size by agarose gel electro-
phoresis. All PCR products were puriﬁed by GFX™ PCR DNA and
Band Puriﬁcation Kit (GE Health Care, UK). The amplicons were
sequenced using the BigDye Terminator v3.1 Cycle Sequencing
kit (Applied Biosystems, UK) in a 3730 DNA Analyzer (ABI, UK)
according to the manufacturer’s instructions using the same pri-
mer sets as for PCR ampliﬁcation. The resulting sequences were
assembled with the SeqMan Pro™ program (Lasergene v.11; DNA-
Star Inc., USA) and aligned with each other using the CLUSTAL W
algorithm (Thompson et al., 1994) in BioEdit 7.0.5.3 (Hall, 1999).
Molecular phylogenetic analyses were performed using MEGA 5.2
(Tamura et al., 2011). The evolutionary history was inferred using
the Neighbor-Joining method (Saitou and Nei, 1987) and conﬁ-
dence on branching was assessed using bootstrap resampling
(1000 replicates) (Felsenstein, 1985). The evolutionary distances
were computed using the Kimura 2-parameter method (Kimura,
1980).3. Results
3.1. Virulent and attenuated virus isolates
Using the species-speciﬁc CaPV real-time PCR method, the vir-
ulent KSGP O-240 isolate was characterized as LSDV. Isiolo and
Kedong SPPV isolates were identiﬁed as GTPVs (Fig. 1).3.2. Vaccines
The attenuated KSGP O-240 vaccine virus present in the Kenya-
vac and KS-1 isolates were identiﬁed as LSDVs. The RM65 strain in
Jovivac and the Romanian SPPV strain in the Saudi Arabian Sheep
Pox Vaccine were conﬁrmed as SPPVs (Fig. 1).
Table 1
The origin, host and reference of the virulent and attenuated capripoxvirus strains.
Strain Origin Host References
KSGP 0-240 field strain Kenya Sheep Davies (1976)
Isiolo SPPV Kenya Sheep Capstick (1959)
Kedong SPPV Kenya Sheep Coakley and Capstick (1961)
KS-1 36 3/95 KSGP 0-240 Sheep Gershon and Black (1989)
Kenyavac KSGP 0-240 Vaccine JOVACa
Jovivac RM65 Vaccine JOVAC
Sheep Pox Vaccine Romanian SPPV Vaccine SAVVIb
SPPV control Mongolian SPPV (2007) Sheep Sample ID: POX-VI-02-07
GTPV control Mongolian GTPV (2008) Goat Sample ID: POX-VI-08-08
LSDV Neethling strain Dr. Erasmus, ARC-OVI, Onderstepoort, SA Cattle Kitching et al., 1989
a JOVAC Jordan Bio-industries Centre.
b SAVVI Saudi Arabian Veterinary and Vaccine Institute.
Fig. 1. Differences in the melting point temperatures for the virulent and attenuated capripoxvirus strains obtained after ﬂuorescence melting curve analysis, using species-
speciﬁc PCR method (Lamien et al., 2011b).
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The sequences of RPO30 and GPCR genes were determined for
the six capripoxviruses under study and submitted to GenBank
(accession numbers KJ818279 to KJ818292). These were compared
with the sequences of capripoxviruses already available on the
public sequence databases.
Molecular phylogenetic analyses were performed on the coding
regions of the RPO30 gene (57 sequences, 609 positions; Fig. 2a)
and the GPCR gene (67 sequences, 1146 positions; Fig. 2b). These
results conﬁrmed the identiﬁcations made using the real-time
PCR. Additionally, the sequence of KS-1 RPO30 gene revealed
two A to G nucleotide substitutions between the KS-1 Pirbright
isolate and the published sequence (GU119932). These are clearly
both A in the new sequence (nucleotide positions 444 and 516
within the RPO30 coding sequence) but do not result in any amino
acid substitutions.4. Discussion
The KSGP O-240 strain has long been considered as the SPPV
reference virus for comparison with LSDV (Davies, 1982). This
strain was chosen for use in vaccines by many vaccine producers
because it was one of the CaPV strains listed as a possible seed
virus for LSD vaccine in the LSDV chapter of the OIE Manual of
Diagnostic Tests and Vaccines for Terrestrial Animals.
Tulman et al. (2002) were the ﬁrst to report similarities in the
pattern of open reading frames of the KS-1 virus and LSDV: ORF
002, 155 and 013 were intact in both KS-1 and LSDV strains,
while these regions were disrupted in other SPPVs. In general,
the importance of this ﬁnding has not been fully appreciated
because the origin of the KS-1 strain was not widely recognized
to be an attenuated strain of KSGP O-240 strain and therefore
LSDV. Because the whole genome of the KSGP O-240 has not
yet been sequenced or published, the ﬁnal conﬁrmation of
Fig. 2. Molecular phylogenetic analysis of (a) the capripoxvirus RNA polymerase subunit (RPO30) gene and (b) the capripoxvirus G-protein-coupled chemokine receptor
(GPCR) gene. The percentage of replicate trees in which the associated taxa clustered together in the bootstrap test (1000 replicates) are shown next to the branches. The tree
is drawn to scale, with branch lengths in the same units as those of the evolutionary distances used to infer the phylogenetic tree. The evolutionary distances are in the units
of the number of base substitutions per site. The sequences determined in this study are marked with a black diamond.
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investigated.
The ﬁndings of our study are in agreement with previously
reported results: the virulent KSGP O-240, the attenuated KSGP
O-240 strain (Kenyavac) as well as the KS-1 isolate were identiﬁed
as LSDV. The real identity of the vaccine virus explains the easyattenuation of the virus for safe use in sheep and goat vaccines.
It is however clear that the level of attenuation of the virus was
insufﬁcient for the use of KSGP O-240 for cattle, in which clinical
disease was observed post-vaccination (Ayelet et al., 2013;
Somasundaram, 2011; Tuppurainen, 2006).
The level of attenuation in Kenyavac is 13–27 passages on lamb
testis cells. In a similar KSGP O-240 vaccine, ‘‘Tissue Culture Sheep
Pox Vaccine’’ (Veterinary Serum and Vaccine Research Institute,
Egypt), that was used against LSDV during the LSD outbreak in
2005–2006 in Egypt, was attenuated three times on choroid plexus
cells, followed by three times on lamb fetal lung cells and three
times on Vero cells (Tuppurainen, 2006). The level of attenuation
is considerably lower than reported for safe use of LSDV in cattle.
The LSD Neethling strain required 60 passages on lamb kidney cells
and 20 on chorioallantoic membrane (Kitching, 2003). The LSD
Madagascan strain was passaged 101 times in rabbit kidney and
5 times in fetal calf kidney cells (Kitching, 2003).
After experimental infection with LSDV only half of the infected
cattle developed clinical disease (Annandale et al., 2013;
Osuagwuh et al., 2007; Tuppurainen et al., 2005) and silent infec-
tions without skin lesions are known to commonly occur in ﬁeld
outbreaks of LSDV (Davies, 1976). In above mentioned animal
experiments, a minimum number of six, highly susceptible, naïve
animals were required in order to produce clinical disease in cattle
challenged with LSDV via an intravenous and/or intradermal route.
This gives guidelines on the animal numbers required for safety
and efﬁcacy experiments for CaPV vaccines.
It was believed that due to the cross-protection within the
genus, any CaPV isolate could be used as a vaccine against LSDV.
However, experience in the ﬁeld setting indicates the superiority
of LSDV vaccines when compared to SPPV vaccines against LSDV.
In addition, according to the previous recommendations for SPPV
vaccines for cattle against LSDV, the suggested titre for RM65 or
Romanian SPPV vaccines is 10–50 times the recommended dose
for sheep (102.5 TCID50), whereas for KSGP O-240 strain an immu-
nizing dose of 103.5 TCID50 was considered desirable for ﬁeld
vaccination campaigns (Davies, 1991). However, these recommen-
dations may be out-of-date and the efﬁcacy of the vaccine should
be re-tested by a challenge experiment in a controlled environ-
ment, using sufﬁciently sensitive testing methods such as real-
time PCR and a sufﬁcient number of fully susceptible cattle.
Due to difﬁculties controlling LSDV by vaccination in the Horn
of Africa and the Middle East (Ayelet et al., 2013; Brenner et al.,
2009; Tuppurainen, 2006), and taking into consideration the dis-
tinct threat of incursion of all CaPV diseases to Europe and Asia,
a new generation of effective and safe vaccines against LSDV, SPPV
and GTPV are urgently required. Ideally the vaccine should be
affordable and available for use both in endemic and non-endemic
countries without adverse effect on global trade of live animals and
their products. None of the currently available CaPV vaccines pro-
vides total protection against LSDV for all vaccinated individuals,
which is a clear disadvantage for control of a vector-borne disease.
In the OIE’s Manual Chapter 2.4.14 – Lumpy skin disease, the
KSGP O-240 strain is mentioned as one of the four CaPV vaccine
strains used for cattle against LSDV. The aim of this report was to
conﬁrm and highlight the most recent molecular ﬁndings, indicat-
ing that the KSGP O-240 vaccine strain is LSDV which at the low
level of attenuation is still virulent for cattle. Consequently, the
identity of the virus in all of the commercially available KSGP O-
240 vaccines is likely to be LSDV instead of SPPV and characteriza-
tion of the vaccine virus should be carried out before use in cattle.
Clinical disease detected in KSGP O-240 vaccinated cattle is more
likely to be caused by insufﬁcient attenuation of the vaccine virus
than incomplete protection and therefore the safety of the vaccines
should be re-evaluated before the vaccine is used for cattle. Addi-
tionally, the use of virulent vaccine may lead to the spread of the
6 E.S.M. Tuppurainen et al. / Antiviral Research 109 (2014) 1–6vaccine virus itself via arthropod vectors. However, sufﬁciently
attenuated KSGP O-240 strain is likely to afford protection for cat-
tle equivalent to other LSDV vaccines.
Due to their broad host-range the Isiolo and Kedong isolates
may provide an alternative vaccine candidate that is effective
against all capripox diseases. Both isolates were collected from
infected sheep, molecular studies identiﬁed both as GTPVs. Most
phylogenetic studies suggest that GTPV is more closely related to
LSDV than SPPV is to LSDV (Lamien et al., 2011a; Le Goff et al.,
2009). In addition, the Isiolo strain has been shown to experimen-
tally infect cattle, while the Kedong vaccine strain protects cattle
against LSDV. This warrants further investigation of the suitability,
efﬁcacy and safety of the Isiolo and Kedong GTP strains, as well as
sufﬁciently attenuated KSGP O-240 and O-180 strains as a basis for
affordable broad-spectrum vaccines against LSDV, SPPV and GTPV.
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